hero_left_circles
Abstracts
 

Late-Breaking Abstracts

hero_right_circles

Policy for Late-Breaking Abstracts

SUBMIT AN ABSTRACT

Abstract Deadlines

  • Late-breaking abstract submissions open: December 6, 2024 

  • Late-breaking abstract submissions close: December 20, 2024 

  • Late-breaking abstract accept/reject notification: Early January   

  • Draft Oral Abstract PowerPoint Due: Wednesday, January 22, 2025 (if accepted) 

  • Final Oral Abstract PowerPoint Due: Friday, January 31, 2025 (if accepted) 

  • Late-breaking abstract embargo lifts: Thursday, February 13, 2025 (if accepted) 

Authors who submitted to the general call for abstracts will receive their decision letter by December 18.

Abstract Eligibility

Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program Co-Chairs. Late-breaking abstracts that are accepted for the 2025 Tandem Meetings will not be published in the February 2025 issue of ASTCT's journal Transplantation and Cellular Therapy

Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission. Data that has been, or will be, presented at any other meeting before being presented at the 2025 Tandem Meetings of ASTCT and CIBMTR, will not be accepted for presentation. Abstracts that were submitted to the call for abstracts should not be resubmitted as late breaking abstracts.

If you submitted an abstract to ASH's annual meeting, please review ASH's copyright policies to ensure that you are in compliance: https://www.hematology.org/meetings/annual-meeting/abstracts/copyright-and-reuse-policy

Conference Registration Fee

Abstract presenting authors will be eligible for the early registration rate even after standard and on-site registration rates apply. 

Abstract Submission Fee

There is a $75 non-refundable abstract submission fee. Abstract submissions that have not paid the fee by December 20, 2024, will be removed from consideration.

Abstract Categories
  • Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML) — Basic/Preclinical 

  • Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML) — Clinical 

  • Acute Regimen-Related Toxicity and Supportive Care 

  • Autoimmune Disorders — Transplant and Effector Cells 

  • Cellular and Gene Therapy — Regulatory and Processing 

  • Conditioning Regimens 

  • Donor Safety, Unique Mobilizations and Health Services 

  • Engineered Immune Cells (CAR-T, NK, TCR): Basic/Preclinical — Antigen Finding, Safety 

  • Engineered Immune Cells (CAR-T, NK, TCR): Clinical — Immune Effector Cells for Heme Malignancies 

  • Engineered Immune Cells (CAR-T, NK, TCR): Clinical — Immune Effector Cells for Solid Tumors 

  • Gene Therapy and Editing 

  • Graft Sources (related, matched and mismatched unrelated, haploidentical, autologous, cord blood, bone marrow and peripheral blood) 

  • Graft-versus-Host and Graft-versus-Tumor — Basic/Preclinical 

  • Graft-versus-Host and Graft-versus-Tumor — Clinical: Prevention, Treatment and Biomarkers 

  • Hematopoietic Stem Cell Niche, Biology, Expansion and Marrow Failure Syndromes 

  • Hemoglobinopathies, Primary Immune Deficiencies and Disregulation and Inborn Errors of Immunity 

  • HSCT, Gene and Other Cellular Therapies in Countries With Constrained Resources 

  • Immune Reconstitution and Immunobiology 

  • Immunogenetics 

  • Intersectionality, Diversity and Inclusion and Removing Barriers to Access 

  • Late Effects, Quality of Life and Accelerated Aging 

  • Lymphoma/CLL — Basic/Preclinical 

  • Lymphoma/CLL — Clinical 

  • Myeloma — Basic/Preclinical 

  • Myeloma — Clinical 

  • Relapse — Basic/Preclinical 

  • Relapse — Clinical: Prevention and Treatment 

  • Study Design and Statistics 

  • Transplant and Cell Therapy for Aged and Geriatric Populations 

Responsibility of Abstract Authors 

The first author listed for each abstract serves as the presenting author and is the primary contact for all correspondence regarding the abstract. If there is a change to the presenting author, please contact tandemabstracts@astct.org

The presenting author is responsible for the following: 

  • Ensuring that all authors have read the abstract and agreed to be co-authors. 

  • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the Tandem Meetings of ASTCT and CIBMTR. 

  • Obtaining all conflict-of-interest disclosure information from co-authors. 

  • Providing justification in the submission form as to why the abstract is late-breaking science. 

  • Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers can focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar, or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission. 

  • Ensuring that they will be prepared to present and to respond to questions regarding the abstract. If that is not the case, the authors should choose a poster as their preference. 

Each abstract author agrees and certifies that they: 

  • Have read the rules and agrees to be bound by them. 

  • Abstracts that were submitted to the call for abstracts should not be resubmitted as late breaking abstracts.

  • Are responsible for submission of the abstract in accordance with the rules and waives any and all claims against ASTCT/CIBMTR/Tandem Meetings of ASTCT and CIBMTR and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts. 

Abstract Review 

Abstracts are peer reviewed on their scientific merits and according to subject category. Individuals submitting abstracts must indicate the appropriate review category. Abstracts may be re-categorized to a more appropriate category based on guidance from the Tandem Meetings Co-Chairs. The ASTCT, CIBMTR and Tandem Meetings of ASTCT and CIBMTR reserve the right to make minor editorial grammatical/spelling changes if required for clarity of presentation. 

Abstract Corrections

All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. Requests for assistance in accessing abstracts to allow for modifications, should be submitted in writing to tandemabstracts@astct.org by December 20, 2024, at 11:59 PM CT. The Tandem Abstracts Team is unable to fulfill any correction requests after this deadline or over the phone.

Abstract Withdrawals

Abstract withdrawals must be requested in writing via email to tandemabstracts@astct.org by December 20, 2024, at 11:59 PM CT. ASTCT and CIBMTR Staff cannot fulfill any withdrawal requests by phone or after the stated deadline.

Incomplete Abstracts 

Any submitted abstract deemed incomplete within the submission system on December 21, 2024, at 12:00 AM CT will be eliminated without further notification prior to abstracts being distributed to 2025 Tandem Meetings abstract reviewers. 

Embargo 

Abstracts submitted for presentation will be embargoed by the author(s) and the 2025 Tandem Meetings, upon submission. 

Late-breaking abstracts submitted for presentation to the 2025 Tandem Meetings will be embargoed by the author(s) and the 2025 Tandem Meetings, upon submission. The embargo will be lifted, and late-breaking abstracts will be made available for viewing on February 13, 2025

Copyright 

Authors assign copyright of the abstract to ASTCT upon submission, unless one of the authors is a U.S. Federal employee. This means that the identical abstract may not be republished or submitted to another meeting; however, Elsevier may grant permission for reuse of abstract content on behalf of ASTCT. You can request to re-use an abstract by clicking here

General Submission Instructions 

  • No names or titles should be included in the abstract text. Names will be automatically hidden during the abstract review process and will be automatically inserted and properly formatted upon publication. 

  • Oral Presentation: 

    • There will be approximately 3-4 abstracts selected for oral presentations during the scientific Late-Breaking Oral Abstract Session. Late-breaking abstracts will not be accepted for poster presentations or published in the February 2025 issue of ASTCT's journal, Transplantation and Cellular Therapy.

    • If your abstract is accepted for oral presentation, you will be required to submit your slides for review by your session moderators AND to upload the final version of your slides before the meeting. These deadlines will be communicated to you, if accepted. 

  • Required elements of this system are designated by a red (*). If you fail to enter the required data, you will be prompted to go back and correct the omission before your abstract can be submitted. 

  • Verify that your abstract is correct by clicking Preview Abstract. 

  • Only when you are sure that your abstract is complete and in final form, click "Submit Abstract". 

  • Presenting authors will be automatically informed of the unique ID numbers and passwords assigned to their abstracts. Abstracts may be viewed and modified at any time between submission and the deadline, using the assigned ID # and password. 

  • Eligibility: If your abstract is accepted for either poster or oral presentations, you can expect the following: 

    • You will not be eligible for a stipend for presenting a poster or oral abstract. 

    • You will be eligible for a registration discount for the Tandem Meetings. 

  • Character Count: There is a limit of 2,500 characters (approximately 300 words) for the body of the abstract. Note that this character count does not include spaces or the title but does include the space allocated to tables. Figures are not included in the character count. 

  • Multiple Abstracts: There are no restrictions on the number of abstracts you may submit, or the number abstracts that you may present. 

  • Attached Figure: You may include up to 3 figures or images with your abstract - all figures and images must have titles. Words in that image or figure are not deducted from the total character count. Figures or images must be combined into one digital file for upload. 

  • Notification: Decisions on abstract acceptance /rejection will be communicated early January 2025. Notification will be sent by email to the presenting author listed on each abstract. 

  • Abstract Corrections: All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. 

  • Incomplete Abstracts: Any submitted abstract deemed incomplete within the submission system on December 21, 2024, 12:00 AM CT will be eliminated without further notification prior to abstracts being distributed to the 2025 Tandem Meetings of ASTCT and CIBMTR abstract review team. 

SUBMIT AN ABSTRACT

Technical Support 

For help in submitting an abstract online, email tandem@confex.com or click on the "Report a Technical Issue" link in the submission application. 

Questions 

For all other questions regarding abstracts, please contact tandemabstracts@astct.org